ReviewBiochemistry2022
Engineered Cancer Targeting Microbes and Encapsulation Devices for Human Gut Microbiome Applications.
Review in Biochemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Innovative approaches in the treatment of hematologic malignancies: the role of CRISPR-engineered microbiomes along the gut-immune axis in immunotherapy development.Cancer cell international · 2026Review
- Hydrogel platforms for engineered live biotherapeutics: materials, microbial integration and clinical potential.RSC pharmaceutics · 2026Review
- Bacteria as living biosensors for DNA.Nature reviews bioengineering · 2026Article
- Strategic modulation of the gastrointestinal microbiome to enhance pancreatic cancer immunotherapy.Drug discovery today · 2025Review
- The antimicrobial metabolite nisin Z reduces intestinal tumorigenesis and modulates the cecal microbiome in ApcMicrobiology spectrum · 2025Article
- Gut microbiota in colorectal cancer: a review of its influence on tumor immune surveillance and therapeutic response.Frontiers in oncology · 2025Review
- An overview of basic pathophysiological interactions between gut bacteria and their host.Frontiers in nutrition · 2025Review
- Engineered microorganisms: A new direction in kidney stone prevention and treatment.Synthetic and systems biotechnology · 2024Review
- Cell-Free Protein Expression in Polymer Materials.ACS synthetic biology · 2024Article
- Engineering bacterial theranostics: from logic gates toFrontiers in bioengineering and biotechnology · 2024Review
- From competition to cure: the development of live biotherapeutic products for anticancer therapy in the iGEM competition.Frontiers in bioengineering and biotechnology · 2024Review
- Harnessing Microbiome Therapy to Treat Metabolic Syndrome.AACE endocrinology and diabetesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The gut microbiota produce specialized metabolites that are important for maintaining host health homeostasis. Hence, unstable production of these metabolites can contribute to diseases such as inflammatory bowel disease and colon cancer. While fecal transplantation or dietary modification approaches can be used to correct the gut microbial community's metabolic output, this Perspective focuses on the use of engineered bacteria. We highlight recent advances in bacterial synthetic biology approaches for the treatment of colorectal cancer and systemic tumors and discuss the functionality and biochemical properties of novel containment approaches using hydrogel-based and electronic devices. Synthetic circuitry refinement and incorporation of novel functional modules have enabled more targeted detection of colonic tumors and delivery of anticancer compounds inside the gastrointestinal (GI) tract, as well as the design of tumor-homing bacteria capable of recruiting infiltrating T cells. Engineering challenges in these applications include the stability of the genetic circuits, long-term engraftment of the chosen chassis, and containment of the synthetic microbes' activity to the diseased tissues. Hydrogels are well-suited to the encapsulationo of living organisms due to their matrix structure and tunable porosity. The matrix structure allows a dried hydrogel to collect and contain GI contents. Engineered bacteria that sense GI tract inflammation or tumors and release bioactive metabolites to the targeted area can be encapsulated. Electronic devices can be enabled with additional measuring and data processing capabilities. We expect that engineered devices will become more important in the containment and delivery of synthetic microbes for diagnostic and therapeutic applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.